In a CFA-induced arthritis model, TRPV1 deletion reduced joint and paw swelling, synovial inflammation, bone erosion and cartilage damage in early stages (≤5 weeks) and suppressed RA-related pain later (>8 weeks) (Refs 72, 73, 74, 75). This evidence concerns the gene TRPV1 and rheumatoid arthritis.